Long-Term Quality of Life after Hybrid Robot-assisted and Open Ivor Lewis Esophagectomy for Esophageal Cancer in a Single Center: a Comparative Analysis

Author:

Neuschütz Kerstin J.1,Fourie Lana1,Germann Nicolas2,Pieters Anouk2,Däster Silvio1,Angehrn Fiorenzo V.1,Klasen Jennifer M.1,Müller-Stich Beat P.1,Steinemann Daniel C.1,Bolli Martin1

Affiliation:

1. Clarunis – University Digestive Health Care Center Basel

2. University of Basel

Abstract

Abstract Purpose Due to improved survival of esophageal cancer patients, long-term quality of life (QoL) is increasingly gaining importance. We analyzed QoL of patients treated with open Ivor Lewis esophagectomy (Open-E) or a hybrid operation including laparotomy and a robot-assisted thoracic phase (hRob-E), as well as a standard group of healthy individuals. Methods With a median follow-up of 36 months after hRob-E (n = 28) and 40 months after Open-E (n = 43), patients´ QoL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30) and the EORTC Esophagus specific QoL questionnaire 18 (QLQ-OES18). Results Patients showed similar clinical-pathological characteristics, but hRob-E patients had significantly higher ASA scores at surgery (p < 0.001). Patients and healthy controls reported similar global health status, emotional and cognitive functions. However, physical functioning of Open-E patients was significantly reduced compared to healthy controls (p = 0.019). Operated patients reported reduced role and social functioning, fatigue, nausea and vomiting, dyspnea and diarrhea. A trend towards a better pain score after hRob-E compared to Open-E emerged (p = 0.063). Regarding QLQ-OES18, hRob-E and Open-E treated patients similarly reported eating problems, reflux, and troubles swallowing saliva. Conclusions The general health status is not impaired after esophagectomy. Despite higher ASA scores, QoL of hRob-E patients is similar to that of patients operated with Open-E. Moreover, patients after hRob-E appear to have a better score regarding physical functioning and a better pain profile than patients after Open-E, indicating a benefit of minimally invasive surgery.

Publisher

Research Square Platform LLC

Reference27 articles.

1. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries;Domper Arnal MJ;World Journal of Gastroenterology,2015

2. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma;Rubenstein JH;Gastroenterology,2015

3. Xu, Q.-L., Li, H., Zhu, Y.-J., & Xu, G. (2020). The treatments and postoperative complications of esophageal cancer: A review. JournalofCardiothoracicSurgery, 15. https://doi.org/10.1186/s13019-020-01202-2

4. Eyck, B. M., van Lanschot, J. J. B., Hulshof, M. C. C. M., van der Wilk, B. J., Shapiro,J., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven,H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., Cuesta, M.A., Blaisse, R. J. B., Busch, O. R., Creemers, G.-J. M., Punt, C. J. A., Plukker,J. T. M., Verheul, H. M. W., … CROSS Study Group. (2021). Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 39(18), 1995–2004. https://doi.org/10.1200/JCO.20.03614

5. Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G.A. P., Hospers, G. A. P., Bonenkamp, J. J., Cuesta, M. A., Blaisse, R. J. B., Busch,O. R. C., Ten Kate, F. J. W., Creemers, G.-J. M., Punt, C. J. A., Plukker, J. T. M.,Verheul, H. M. W., Bilgen, E. J. S., … CROSS study group. (2015). Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. The Lancet. Oncology, 16(9), 1090–1098. https://doi.org/10.1016/S1470-2045(15)00040-6

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3